Trefoil Therapeutics Partners With Price Vision Group for Patients with Corneal Endothelial Dystrophies

August 19, 2020 by Sam Ven1

Trefoil Therapeutics Begins First Clinical Trial at Price Vision Group for Patients with Corneal Endothelial Dystrophies

SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. To read the full press release, please click here.

 


One comment

  • Michelle Foote

    September 9, 2020 at 2:07 pm

    I am 70 years old with Fuch’s dystrophy and was referred to Dr. Stephen Johnson by Dr. David Box in October 2017 for a corneal transplant consultation. He advised an endothelial keratoplasty but the post treatment was lying flat on my back for 48 hours. I didn’t think I could do that. I am interested in your clinical trial (or future trials) for regenerative treatment. You actually performed a keratoplasty in 1991 with a follow up of a para plana vitrectomy in 1992 on my mother, Kathryn Stewart. I look forward to hearing from you.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *


Price Vision Group logo horiz white

Price Vision Group is a global leader in corneal transplant, cataract surgery, keratoconus treatment, PRK and LASIK. At our center in Indianapolis, we see patients from Indiana cities including Zionsville, Fishers, Carmel, Noblesville, Avon, and Greenwood, as well as people who travel from across the U.S. and even abroad for treatment by our renowned physicians.

Copyright 2022 Price Vision Group. All rights reserved.